Innocrin Names New CEO and Gets Fast-tracked by FDA for Breast Cancer Treatment Seviteronel
News
Innocrin Pharmaceuticals has named Fred Eshelman, PharmD, as its new CEO and learned it was granted a second fast track designation for seviteronel (VT-464) for the treatment of several types of ... Read more